Statement on release of Release of Health Canada Final Report of the Expert Panel on Immune Globulin
CIPO welcomes the panel’s recognition of the life-dependency need of IG for primary immunodeficiency patients. A prioritized supply of IG for primary immunodeficiency patients is within CIPO’s national and international Principles of Care.
We agree with the panel that ‘creative options should be carefully examined to ensure that all source plasma collected from Canada from Canadian donors (whether paid or volunteer) be made available for the needs of Canadian patients’.
We will continue to work with Canadian Blood Services, our industry partners, patient organizations, provincial and territorial government, Health Canada and other organizations in order to ensure a safe and secure access of supply to IG therapy for PI patients in Canada.
CIPO extends their thanks to the members of the expert panel and to Health Canada.